vimarsana.com
Home
Live Updates
Carisma Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT-0525, a Novel HER2-Targeting CAR-Monocyte : vimarsana.com
Carisma Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT-0525, a Novel HER2-Targeting CAR-Monocyte
/PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and...
Related Keywords
Chicago ,
Illinois ,
United States ,
Philadelphia ,
Pennsylvania ,
American ,
Davendra Sohal ,
Shveta Dighe ,
Eugenep Kennedy ,
Drug Administration ,
Nasdaq ,
Carisma Therapeutics Inc ,
American Society Of Clinical Oncology ,
Company Annual Report On Form ,
University Of Cincinnati Cancer Center ,
Exchange Commission ,
Carisma Therapeutics ,
Chief Medical Officer ,
Cincinnati Cancer ,
American Society ,
Clinical Oncology ,
Private Securities Litigation Reform Act ,
Annual Report ,
Quarterly Reports ,
vimarsana.com © 2020. All Rights Reserved.